三生制药(01530)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01530 三生制药

已收盘 09-15 16:08:29

16.030

-0.190

-1.17%

最高16.290	最低15.950	成交量1,023万
今开16.210	昨收16.220	日振幅2.10%
总市值404.60亿	流通市值404.60亿	总股本25.24亿
成交额1.64亿	换手率0.41%	流通股本25.24亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01530","market":"HK","secType":"STK","nameCN":"三生制药","latestPrice":16.03,"timestamp":1789459709003,"preClose":16.22,"halted":0,"volume":10229944,"delay":0,"changeRate":-0.011713933415536235,"floatShares":2524000000,"shares":2524000000,"eps":4.008429086915594,"marketStatus":"已收盘","change":-0.19,"latestTime":"09-15 16:08:29","open":16.21,"high":16.29,"low":15.95,"amount":164003573,"amplitude":0.020962,"askPrice":16.03,"askSize":24000,"bidPrice":16.01,"bidSize":1500,"shortable":3,"etf":0,"ttmEps":3.7969137499686223,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789522200000},"marketStatusCode":5,"adr":0,"listingDate":1433952000000,"exchange":"SEHK","adjPreClose":16.22,"dividendRate":0.016384,"openAndCloseTimeList":[[1789435800000,1789444800000],[1789448400000,1789459200000]],"volumeRatio":0.478714,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"SBI.HK","impliedVol":0.4949,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/01530","defaultTab":"news","newsList":[{"id":"1110389318","title":"三生制药：9月14日回购20万股股份，耗资约309.40万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1110389318","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110389318?lang=zh_cn&edition=full","pubTime":"2026-09-14 18:16","pubTimestamp":1789380987,"startTime":"0","endTime":"0","summary":"三生制药于2026年9月14日发布翌日披露报表，宣布开展股份回购。该公司于当日通过香港联交所场内方式，以每股15.47港元的价格回购普通股20万股，占回购前公司已发行股本约0.01%，合计支付金额3,094,000港元。回购授权于2026年6月25日获股东大会通过，可回购股份总数为253,707,141股。三生制药确认，此次股份回购符合《香港联合交易所有限公司证券上市规则》等相关法规。公告由公司秘书黎少娟签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"三生制药：9月14日回购20万股股份，耗资约309.40万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667576906","title":"三生制药(01530)9月14日斥资309.4万港元回购20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2667576906","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667576906?lang=zh_cn&edition=full","pubTime":"2026-09-14 18:15","pubTimestamp":1789380928,"startTime":"0","endTime":"0","summary":"智通财经APP讯，三生制药(01530)发布公告，于2026年9月14日，该公司斥资309.4万港元回购20万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495736.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000165453.HKD","BK1583","BK1161","BK1593","01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667608630","title":"港股异动 | 创新药概念股全线走高 WCLC临床数据重磅催化 机构指回调后配置价值凸显","url":"https://stock-news.laohu8.com/highlight/detail?id=2667608630","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667608630?lang=zh_cn&edition=full","pubTime":"2026-09-14 13:39","pubTimestamp":1789364389,"startTime":"0","endTime":"0","summary":"消息面上，9月12-15日，2026年世界肺癌大会召开，多项中国创新药临床数据集中亮相，康方生物依沃西单药OS数据、B7H3ADC等成为焦点。中泰证券指出，WCLC集中披露的多项肺癌领域临床进展，进一步验证了中国创新药的临床价值和全球竞争力，或可积极把握创新药回调后的配置机会。机构普遍认为，三季度部分企业新增订单进入收入确认期，基本面有望持续改善。当前医药板块估值27倍PE，低于历史均值，回调后配置价值凸显。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495523.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0561508036.HKD","KCAI","LU0634319403.HKD","06978","LU1961090484.USD","IBBQ","KURE","159992","BK4588","LU0348767384.USD","01177","LU0348735423.USD","LU0455707207.USD","LU2476274308.USD","LU0607220059.USD","BK1593","LU0348784397.USD","LU2488822045.USD","IE00B543WZ88.USD","IE00BPRC5H50.USD","LU0417516571.SGD","LU0417516738.SGD","01801","LU2097828805.USD","LU2097828714.EUR","HK0000165453.HKD","LU0348827113.USD","MEDX","LU2476274720.SGD","09969","LNGR","LU1831875114.USD","09926","LU0244354667.USD","LU1188198961.HKD","LU0348825331.USD","LU2097828557.USD","BK1574","LU0326950275.SGD","LU1969619763.USD","BK1191","LU0348766576.USD","01530","BK1161","IE00BZ08YR35.GBP","BK1521","LU2242644610.SGD","LU2778985437.USD","BK1589","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117080279","title":"异动解读｜三生制药盘中上涨5.31%，连续大手笔回购叠加高管增持提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1117080279","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117080279?lang=zh_cn&edition=full","pubTime":"2026-09-14 11:05","pubTimestamp":1789355148,"startTime":"0","endTime":"0","summary":"9月14日，三生制药盘中上涨5.31%，报16.26港元，成交额1.38亿港元。消息面上，公司近期持续加大回购力度，9月10日单日斥资约6263万港元回购400万股，9月11日再度回购19万股；执行董事兼主席娄竞于9月7日以每股16.00港元增持49万股，涉资约784万港元，好仓比例升至21.13%。生物科技板块今日整体走强，康方生物涨6.7%、科伦博泰生物涨3.53%，板块情绪亦构成支撑。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"三生制药盘中上涨，大手笔回购增持提振信心","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111186707","title":"三生制药回购19万股股份，耗资约288.08万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1111186707","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111186707?lang=zh_cn&edition=full","pubTime":"2026-09-11 18:16","pubTimestamp":1789121773,"startTime":"0","endTime":"0","summary":"三生制药于2026年9月11日发布翌日披露报表，宣布当天在香港联交所场内回购公司普通股190,000股，占该日前现有已发行股本的约0.01%。回购价格介乎每股15.13港元至15.17港元，总支出2,880,820港元。该回购根据公司于2026年6月25日通过的购回授权进行，授权可回购股份总数为253,707,141股，截至目前公司已在港交所及其他证券交易所合计回购13,197,500股，约占购回授权通过时公司已发行股份的0.52%。公司确认此项回购行为已遵守香港联交所证券上市规则及相关法律法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"三生制药回购19万股股份，耗资约288.08万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131586261","title":"三生制药：2026年9月10日回购400万股，耗资约6,262.93万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1131586261","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131586261?lang=zh_cn&edition=full","pubTime":"2026-09-10 18:41","pubTimestamp":1789036914,"startTime":"0","endTime":"0","summary":"2026年9月10日，三生制药（股票代码：01530）披露翌日报表，宣布于香港联交所场内回购普通股4,000,000股，约占该公司当日现有已发行股本的0.16%。本次回购价格介乎每股港元15.50至15.75，合计耗资约6,262.93万港元。回购完成后，公司已发行股份总数变动为2,524,243,912股，库藏股增加至14,020,500股。\n此前，公司已于2026年6月25日通过购回授权，可回购股份的总数为253,707,141股，迄今已累计回购13,007,500股。本次回购行为遵守香港联交所证券上市规则及适用法律规定。上述公告由公司秘书黎少娟签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"三生制药：2026年9月10日回购400万股，耗资约6,262.93万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666673645","title":"三生制药(01530)9月10日斥资6262.93万港元回购400万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2666673645","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666673645?lang=zh_cn&edition=full","pubTime":"2026-09-10 18:36","pubTimestamp":1789036592,"startTime":"0","endTime":"0","summary":"智通财经APP讯，三生制药(01530)发布公告，于2026年9月10日，该公司斥资6262.93万港元回购400万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494535.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","HK0000165453.HKD","BK1593","01530","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666831355","title":"瑞银：中国制药股上半年业绩好坏参半 首选先声药业(02096)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666831355","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666831355?lang=zh_cn&edition=full","pubTime":"2026-09-09 15:43","pubTimestamp":1788939780,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞银发布研报称，中国制药股上半年业绩好坏参半，在九家评级的制药公司中，有五家业绩好过市场预期，分别为翰森制药、先声药业、中国生物制药、石药集团及科伦药业，联邦制药表现大致符合预期，而三生制药及华东医药表现则逊预期，全数给予“买入”评级。瑞银列先声药业行业首选股，指出先声药业是唯一上调2026年指引的公司，经调整纯利增长目标由30%上调至45%，收入增长维持30%，给予目标价16.6港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493826.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BZ08YR35.GBP","IE00BZ08YT58.USD","IE00B3M56506.USD","01177","IE00BZ08YS42.EUR","BK1593","BK1521","BK1583","HK0000165453.HKD","BK1161","BK1515","BK1589","BK1574","03933","03692","01477","BK1191","01530","02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101822470","title":"三生制药：娄竞增持，好仓比例升至21.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=1101822470","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101822470?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:32","pubTimestamp":1788773538,"startTime":"0","endTime":"0","summary":"娄竞于2026年9月7日以每股均价16.0港元买入三生制药股份49.00万股，涉资约784.00万港元。娄竞此次增持前持有三生制药好仓5.34亿股，占比21.11%；增持后持股量为5.34亿股，好仓比例升至21.13%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665398249","title":"【券商聚焦】中信建投：上半年收入与利润双增，医药行业步入新发展周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2665398249","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665398249?lang=zh_cn&edition=full","pubTime":"2026-09-07 09:04","pubTimestamp":1788743053,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指，2026年上半年医药行业整体收入与扣非净利润实现双增长，创新药、CXO、制药装备及科学试剂等板块积极复苏，行业步入新发展周期。创新药收入+58.68%，扭亏为盈，出海总金额超900亿美元，全年有望超越2025年水平，国际化持续兑现；CXO收入+25.2%，扣非净利润+66.5%，订单旺盛，上行周期确立。随着集采出清、创新放量、出海落地及上游国产化提升，行业有望开启高质量发展周期，龙头将持续受益。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990791","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","LU1115378108.SGD","02196","BK1585","BK1588","HK0000165453.HKD","BK1207","06821","02268","BK1583","KURE","BK1515","SG9999004311.SGD","09926","LU0588546209.SGD","LU2399975544.HKD","LU2488822045.USD","BK1141","02367","01789","KCE","LU1770034418.SGD","601066","BK1161","LU0417516902.SGD","BK1100","BK1197","01099","LU2328871848.SGD","09688","LU0348825331.USD","LU0348827113.USD","LU1720050803.USD","LU2476274720.SGD","IE00B3M56506.USD","01530","02228","LU0640798160.USD","LU0228659784.USD","BK1191","06160","LU0828237510.HKD","IE00B5MMRT66.SGD","BK1500","LU2778985437.USD","LU2476274308.USD","03933","LU1969619763.USD","BK1593","IE00BPRC5H50.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664238859","title":"【券商聚焦】交银国际：医药行业收入稳健增长 多重利好推动盈利表现显著改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2664238859","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664238859?lang=zh_cn&edition=full","pubTime":"2026-09-04 09:00","pubTimestamp":1788483634,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，1H26港股/A股医药行业整体收入增长4.7%/3.2%。创新药产业链增速领跑行业，服务板块复苏：1）港股/A股CXO收入整体增长29.2%/25.3%，（扣非）净利润增长23.4%/67.6%，在各子板块中增速最快，行业整体景气度和订单需求处于高位。2）核心成药板块收入增长17.8%/3.4%、利润增长62.7%/35.0%。其中生物药增速远超化药，在板块收入中的占比也进一步提升。3）医院、器械、诊断、疫苗等板块业绩有复苏趋势。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990646","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000306685.HKD","01951","02596","02096","03329","06078","LU0315179316.USD","LU1152091168.USD","LU2543165471.USD","BK1515","01530","01801","LU0856984785.SGD","LU1880383366.USD","IE00B0JY6N72.USD","03692","03759","06990","BK1209","00013","02269","09966","LU1251922891.USD","IE00B543WZ88.USD","01952","09996","HK0000320264.USD","LU0327786744.USD","01276","06996","BK1589","IE00B5MMRT66.SGD","02273","LU0307460666.USD","LU0348783233.USD","01093","KURE","KCE","LU0039217434.USD","LU0588546209.SGD","01177","06160","SG9999004220.SGD","01548","09926","BK1161","02162","02268","LU1242518857.USD","06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664870226","title":"【生物医药小白投研】第八篇：小白完整投研框架与体系复盘","url":"https://stock-news.laohu8.com/highlight/detail?id=2664870226","media":"港股解码","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664870226?lang=zh_cn&edition=full","pubTime":"2026-09-03 16:10","pubTimestamp":1788423000,"startTime":"0","endTime":"0","summary":"经过前七篇的认知、排雷、管线、赛道、BD、估值、交易节奏全维度学习，本篇作为专栏终章，复盘整套投研体系，整合核心知识点，帮助新手建立系统化的投资决策习惯。对仅有纸面高额交易额、低首付、小公司噱头BD的标的保持警惕。作者丨吴言编辑丨Jasmine往期推荐:第七篇：看得懂基本面，更要把握交易节奏第六篇：小白也能上手的医药股估值与前景打分体系第五篇：读懂BD的价值逻辑第四篇：分清黄金赛道与内卷红海","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzI2MDAzMTQ4OA==&mid=2650514079&idx=1&sn=b343b5c979b09868c5b4b6ffa6bf3616&chksm=f3613873bcb2e49ac858ccd3d88ca34c5f10e2143037b5c049e758da1d990257cd4b54d9d0b6&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["LU2097828631.EUR","BK1500","BK1515","LU0067412154.USD","KURE","LU1251922891.USD","LU0880133367.SGD","LU1960683339.HKD","LU0828237510.HKD","LU1813983027.USD","SG9999004220.SGD","LU0348735423.USD","02269","LU0455707207.USD","LU0856984785.SGD","03692","LU0359202008.SGD","LU1880383366.USD","LU1720050803.USD","IE00BZ08YT58.USD","LU2488822045.USD","LU2097828474.EUR","IE00B0JY6N72.USD","LU1794554557.SGD","01801","LU0181495838.USD","LU0320764599.SGD","06160","HK0000165453.HKD","LU1807302812.USD","LU0359201612.USD","LU1008478684.HKD","LU2039709279.SGD","LU1328277881.USD","LU0244354667.USD","LU0051755006.USD","LU1188198961.HKD","LU0128526141.USD","LU1969619763.USD","BK1583","LU0456846285.SGD","01530","BK1588","LU0072913022.USD","LU0516423174.USD","01093","LU0029874061.USD","LU2242644610.SGD","LU0572944931.SGD","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176098747","title":"三生制药9月2日回购150万股股份，涉资约2,358.50万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1176098747","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176098747?lang=zh_cn&edition=full","pubTime":"2026-09-02 19:31","pubTimestamp":1788348707,"startTime":"0","endTime":"0","summary":"三生制药(01530)于2026年9月2日公告，公司在香港联交所场内回购普通股合计150万股，占当日回购前公司已发行股本0.06%，每股回购价格介乎港币15.70元至15.75元，合计涉资约2,358.50万港元。回购完成后，公司已发行股本减少至2,528,243,912股，库藏股数量增至10,020,500股。\n根据公告，购回授权于2026年6月25日获得通过，公司可回购的总股份数为253,707,141股。截至目前，已累计回购9,007,500股，余下可回购股份数为244,699,641股。公司确认此次回购过程符合香港联交所证券上市规则及相关法规要求。\n本公告由公司秘书黎少娟签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"三生制药9月2日回购150万股股份，涉资约2,358.50万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664181643","title":"三生制药(01530)9月2日斥资2358.5万港元回购150万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2664181643","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664181643?lang=zh_cn&edition=full","pubTime":"2026-09-02 19:29","pubTimestamp":1788348580,"startTime":"0","endTime":"0","summary":"智通财经APP讯，三生制药(01530)发布公告，于2026年9月2日斥资2358.5万港元回购150万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491146.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000165453.HKD","BK1593","BK1583","BK1161","01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100725998","title":"三生制药更新8月股份变动月报表，股本小幅增加","url":"https://stock-news.laohu8.com/highlight/detail?id=1100725998","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100725998?lang=zh_cn&edition=full","pubTime":"2026-09-02 16:37","pubTimestamp":1788338235,"startTime":"0","endTime":"0","summary":"三生制药于2026年9月2日发布截至2026年8月31日止的股份变动月报。公告显示，公司法定注册股本维持在50,000,000,000股普通股，每股面值0.00001美元，注册股本金500,000美元，与上月保持一致。公告未披露任何购回或注销股份事项。当月股份变动主要来自2015年5月23日采纳并于2016年6月28日修订的股份期权计划。期间共有25,000股期权被行使，行使价每股7.62港元，合计筹资190,500港元。本次月报由公司秘书黎少娟签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663944021","title":"里昂：降三生制药(01530)目标价至30.4港元 维持“跑赢大市”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2663944021","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663944021?lang=zh_cn&edition=full","pubTime":"2026-08-31 11:40","pubTimestamp":1788147600,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，里昂发布研报称，三生制药(01530)上半年业绩受惠于707里程碑收入及CDMO业务强劲增长，抵销了核心产品销售疲弱的影响。虽然近期收入增长仍然低迷，但新一轮产品上市周期及707全球开发项目的进一步进展，应能支持中期增长。该行维持予其“跑赢大市”评级，目标价由32.6港元下调至30.4港元。该股现持有逾186亿元人民币现金，撇除现金后，现交易于预测未来一年市盈率7.4倍。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489266.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159431755","title":"异动解读｜三生制药盘中下跌5.07%，辉瑞BD折价配股落地叠加板块整体承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1159431755","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159431755?lang=zh_cn&edition=full","pubTime":"2026-08-31 10:24","pubTimestamp":1788143043,"startTime":"0","endTime":"0","summary":"8月31日，三生制药盘中下跌5.07%，报16.1港元，成交额1.78亿港元。消息面上，三生制药与辉瑞的重大BD交易正式落地，公司以折价约17%向辉瑞配售新股，市场担忧短期股权稀释压力。此前辉瑞以超60亿美元引进三生制药PD-1/VEGF双抗SSGJ-707，正在全球推进多项三期临床。同时，公司上半年归母净利润同比下滑15.6%至11.47亿元，传统产品销售收入同比下降19.3%，内生业务承压已被多家券商确认。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"辉瑞折价配股落地，三生制药承压走低","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662094216","title":"【生物医药小白投研】第五篇：读懂BD的价值逻辑","url":"https://stock-news.laohu8.com/highlight/detail?id=2662094216","media":"港股解码","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662094216?lang=zh_cn&edition=full","pubTime":"2026-08-28 16:50","pubTimestamp":1787907000,"startTime":"0","endTime":"0","summary":"在生物医药二级市场，BD是出现频率最高、对股价影响较为直接的核心词汇之一。但在A股、港股创新药赛道，能够对股价形成重大催化的BD交易，大多特指药物全球权益授权交易。首付款是海外顶级药企对药物当下真实价值的投票，是BD含金量的核心判断依据。BD出海让一款药物同时覆盖国内+全球市场，估值逻辑彻底升级。例如科伦博泰、信达生物等，持续兑现出海BD，研发实力全球认可。NO.6小白必须警惕以下BD误区误区一：BD落地股价必涨。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzI2MDAzMTQ4OA==&mid=2650514013&idx=2&sn=a94c778f97f0744682cc347b39421f20&chksm=f382c39a6e71d39b1967e69c7fe65ec399f4658e5a18b93c3b2c95e183487c32d8cdc7dd65d9&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["06160","LU0326950275.SGD","LU2097828805.USD","LU0244354667.USD","LU0455707207.USD","LU2097828474.EUR","LU1251922891.USD","KURE","ONC","BK1583","BK1593","LU2488822045.USD","688235","LU0588546209.SGD","LU1719994722.HKD","06990","HK0000165453.HKD","LU0307460666.USD","LU1188198961.HKD","LU0228659784.USD","LU2328871848.SGD","LU2242644610.SGD","LU0828237510.HKD","LU0463099449.HKD","LU1969619763.USD","01801","LU2097828557.USD","LU1303224171.USD","LU0502904849.HKD","01530","BK1588","LU2097828714.EUR","BK1161","LU0196878994.USD","BK1500","BK1589","LU1770034418.SGD","LU2097828631.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662760675","title":"【券商聚焦】国信证券维持三生制药（01530）优于大市评级 指707有望成重磅炸弹","url":"https://stock-news.laohu8.com/highlight/detail?id=2662760675","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662760675?lang=zh_cn&edition=full","pubTime":"2026-08-26 14:01","pubTimestamp":1787724066,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国信证券发布研报指，三生制药 2026年上半年实现营收45.26亿元人民币，毛利率为83.8%，其中产品销售收入34.43亿元、授权收入8.52亿元、CDMO业务收入2.31亿元；归母净利润11.47亿元，经调整的经营性归母净利润14.36亿元。CDMO基地沈阳德生已为辉瑞提供临床药品原液，未来将持续供货。707快速开启全球3期多中心临床，有望成为重磅炸弹，维持“优于大市”评级。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/MTU3MGM5Y2M3ZDk5Mjg2ODIwNjM2NDU0OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MTU3MGM5Y2M3ZDk5Mjg2ODIwNjM2NDU0OA==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989481","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCE","002736","01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661223843","title":"【券商聚焦】招银国际维持三生制药（01530）“买入”评级 707的全球临床推进仍是主要上行催化","url":"https://stock-news.laohu8.com/highlight/detail?id=2661223843","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661223843?lang=zh_cn&edition=full","pubTime":"2026-08-24 13:22","pubTimestamp":1787548948,"startTime":"0","endTime":"0","summary":"金吾财讯 | 招银国际研报指，三生制药 1H26实现营收45.3亿元，主要得益于707里程碑收入贡献；剔除授权收入后的常规业务收入36.7亿元，反映增值税调整、医保控费及VBP带来的压力。该机构认为市场已对2026年产品销售端的短期压力有所预期，而707的全球重磅潜力仍是主导上行因素。该机构下调近期产品销售预测以反映传统产品持续承压，但鉴于辉瑞全球临床开发的快速推进，上调2026E里程碑收入预测。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/YzM1MzBiNWM5MmUxNDYxMGFiODk0MWI5MWJmNTU3YjMxMTA4MTkwNzI1ODY3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YzM1MzBiNWM5MmUxNDYxMGFiODk0MWI5MWJmNTU3YjMxMTA4MTkwNzI1ODY3.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989178","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530","KCE"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.3sbio.com","stockEarnings":[{"period":"1week","weight":0.0112},{"period":"1month","weight":-0.0747},{"period":"3month","weight":-0.0012},{"period":"6month","weight":-0.2978},{"period":"1year","weight":-0.4942},{"period":"ytd","weight":-0.3193}],"compareEarnings":[{"period":"1week","weight":-0.0195},{"period":"1month","weight":-0.0079},{"period":"3month","weight":0.0173},{"period":"6month","weight":-0.0426},{"period":"1year","weight":-0.0557},{"period":"ytd","weight":-0.0278}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"3SBio Inc是一家主要从事生物制药产品的开发、生产、市场推广及销售的投资控股公司。该公司的主要产品包括特比澳、益比奥、益赛普、赛普汀等生物药物以及蔓迪、丽美治等小分子药物。该公司还从事为客户提供多种生物药的研发生产以及治疗技术平台服务的合同开发与生产运营（CDMO）业务。该公司的产品主要应用于血小板减少症（CIT）、慢性肾病（CKD）引起的贫血症、治疗化疗引起的贫血症（CIA）、强直性嵴柱炎（AS）及银屑病等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":-0.006634},{"month":2,"riseRate":0.454545,"avgChangeRate":0.001777},{"month":3,"riseRate":0.818182,"avgChangeRate":0.113184},{"month":4,"riseRate":0.454545,"avgChangeRate":-0.011081},{"month":5,"riseRate":0.636364,"avgChangeRate":0.080953},{"month":6,"riseRate":0.727273,"avgChangeRate":0.025359},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.034677},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.015863},{"month":9,"riseRate":0.666667,"avgChangeRate":0.025704},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.018318},{"month":11,"riseRate":0.727273,"avgChangeRate":0.059928},{"month":12,"riseRate":0.454545,"avgChangeRate":-0.045348}],"exchange":"SEHK","name":"三生制药","nameEN":"3SBIO"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"三生制药(01530)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供三生制药(01530)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"三生制药,01530,三生制药股票,三生制药股票老虎,三生制药股票老虎国际,三生制药行情,三生制药股票行情,三生制药股价,三生制药股市,三生制药股票价格,三生制药股票交易,三生制药股票购买,三生制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"三生制药(01530)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供三生制药(01530)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}